Research Paper Volume 16, Issue 12 pp 10546—10562

Figure 1. NAT1 has low expression in patients with colorectal cancer and patients with liver metastasis. (A) TCGA database showed that the expression level of NAT1 was low in patients with colorectal cancer; (B) The expression of NAT1 was lower in colorectal cancer patients with higher stage; (C) Overall survival was longer in patients with high NAT1 expression; (D) NAT1 was statistically different in different stages of colorectal cancer; (E) Immunohistochemical results of tissue chips showed that patients with higher NAT1 expression had longer survival; (F, G) Immunohistochemical results showed that the level of NAT1 in colon cancer tissues of patients with liver metastasis was lower (P < 0.05).